Hepatobiliary associations with inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 6, 2009, Pages 681-691

  Knight, Crystal ^a   Murray, Karen F ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune hepatitis; Hepatotoxicity; Inflammatory bowel disease; Infliximab; Overlap syndrome; Primary sclerosing cholangitis; Thiopurine

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CLADRIBINE; COLCHICINE; CYCLOSPORIN A; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; PENICILLAMINE; PENTOXIFYLLINE; PLACEBO; PREDNISONE; STEROID; TACROLIMUS; URSODEOXYCHOLIC ACID; VANCOMYCIN;

AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; BILE DUCT CARCINOMA; CANCER RADIOTHERAPY; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; HEPATOBILIARY DISEASE; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; SIDE EFFECT; ULCERATIVE COLITIS;

CHOLANGITIS, SCLEROSING; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; STEROIDS; URSODEOXYCHOLIC ACID;

EID: 73449119611     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.53     Document Type: Review

References (90)

1. Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm. Bowel Dis. 14(6), 738-743 (2008).
2. Bernstein CN. Extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 3(6), 477-483 (2001).
3. Gohlke F, Lohse AW, Dienes HP et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J. Hepatol. 24(6), 699-705 (1996).
4. Lohse AW, zum Buschenfelde KH, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 29(4), 1078-1084 (1999).
5. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am. J. Gastroenterol. 102(7), 1518-1527 (2007). Thiopurine metabolism and associated hepatotoxicity.
6. Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am. J. Gastroenterol. 102(2), 344-350 (2007).
7. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin. Gastroenterol. Hepatol. 7(2), 239-245 (2009). One of the largest single-center studies of children with primary sclerosing cholangitis (PSC).
8. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am. J. Gastroenterol. 102(5), 1042-1049 (2007).
9. Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis - aetiopathogenesis, autoimmunity, management and malignancy. J. Hepatol. 48(Suppl. 1), S38-S57 (2008). Excellent review of up-to-date knowledge of the the pathogenesis and treatment of PSC.
10. Baumgart DC. What's new in inflammatory bowel disease in 2008? World J. Gastroenterol. 14(3), 329-330 (2008).
11. Sokol H, Cosnes J, Chazouilleres O et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J. Gastroenterol. 14(22), 3497-3503 (2008).
12. Loftus EV Jr, Harewood GC, Loftus CG et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54(1), 91-96 (2005).
13. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J. Gastroenterol. Hepatol. 20(3), 366-370 (2005).
14. Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125(5), 1364-1369 (2003).
15. Chapman RW, Arborgh BA, Rhodes JM et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21(10), 870-877 (1980).
16. Loftus EV Jr, Sandborn WJ, Tremaine WJ et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 110(5), 1496-1502 (1996).
17. van Erpecum KJ, Smits SJ, van de Meeberg PC et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 110(5), 1503-1506 (1996).
18. Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J. Gastroenterol. 14(21), 3338-3349 (2008). In-depth discussion of the etiology of PSC.
19. Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J. Gastroenterol. 14(21), 3350-3359 (2008).
20. Bergquist A, Montgomery SM, Bahmanyar S et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin. Gastroenterol. Hepatol. 6(8), 939-943 (2008).
21. Chapman RW, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut 24(1), 38-41 (1983).
22. Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of primary sclerosing cholangitis with HLA-DRw52a. N. Engl. J. Med. 322(26), 1842-1844 (1990).
23. Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 35(8), 555-564 (2002).
24. Boberg KM, Spurkland A, Rocca G et al. The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand. J. Gastroenterol. 36(8), 886-890 (2001).
25. Krasinskas AM, Yao Y, Randhawa P, Dore MP, Sepulveda AR. Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig. Dis. Sci. 52(9), 2265-2270 (2007).
26. Mehal WZ, Hattersley AT, Chapman RW, Fleming KA. A survey of cytomegalovirus (CMV) DNA in primary sclerosing cholangitis (PSC) liver tissues using a sensitive polymerase chain reaction (PCR) based assay. J. Hepatol. 15(3), 396-399 (1992).
27. Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K, Kelly JK. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 5(1), 8-13 (1987).
28. Kulaksiz H, Rudolph G, Kloeters-Plachky P, Sauer P, Geiss H, Stiehl A. Biliary Candida infections in primary sclerosing cholangitis. J. Hepatol. 45(5), 711-716 (2006).
29. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 95(11), 3195-3199 (2000).
30. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 79(2), 200-206 (1980).
31. Barbatis C, Grases P, Shepherd HA et al. Histological features of sclerosing cholangitis in patients with chronic ulcerative colitis. J. Clin. Pathol. 38(7), 778-783 (1985).
32. Weber C, Kuhlencordt R, Grotelueschen R et al. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy 40(9), 739-745 (2008).
33. Chavhan GB, Roberts E, Moineddin R, Babyn PS, Manson DE. Primary sclerosing cholangitis in children: utility of magnetic resonance cholangiopancreatography. Pediatr. Radiol. 38(8), 868-873 (2008).
34. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27(2), 311-316 (1998).
35. Chalasani N, Baluyut A, Ismail A et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31(1), 7-11 (2000).
36. Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am. J. Gastroenterol. 102(8), 1677-1682 (2007).
37. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48(4), 1106-1117 (2008). Large study evaluating the test performance of different modalities for the detection of cholangiocarcinoma.
38. Prytz H, Keiding S, Bjornsson E et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44(6), 1572-1580 (2006).
39. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J. Hepatol. 50(1), 158-164 (2009).
40. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26(1), 31-41 (2006).
41. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22(5), 1404-1408 (1995).
42. Hirano K, Tada M, Isayama H et al. Clinical features of primary sclerosing cholangitis with onset age above 50 years. J. Gastroenterol. 43(9), 729-733 (2008).
43. Bjornsson E. Small-duct primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 11(1), 37-41 (2009).
44. Bjornsson E, Olsson R, Bergquist A et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134(4), 975-980 (2008).
45. Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol. Ther. 13(8), 979-996 (1999).
46. Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31(2), 318-323 (2000).
47. Chen W, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. CochraneDatabase Syst. Rev. (3), CD004036 (2004).
48. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J. Clin. Gastroenterol. 39(2), 168-171 (2005).
49. Duchini A, Younossi ZM, Saven A, Bordin GM, Knowles HJ, Pockros PJ. An openlabel pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J. Clin. Gastroenterol. 31(4), 292-296 (2000).
50. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 49(1), 1-4 (2004).
51. Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95(9), 2338-2342 (2000).
52. Olsson R, Broome U, Danielsson A et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 108(4), 1199-1203 (1995).
53. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur. J. Gastroenterol. Hepatol. 13(2), 171-175 (2001).
54. Klingenberg SL, Chen W. D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst. Rev. (1), CD004182 (2006).
55. Farkkila M, Karvonen AL, Nurmi H et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40(6), 1379-1386 (2004).
56. Smith T, Befeler AS. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 9(1), 54-59 (2007).
57. Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin. Proc. 75(7), 688-694 (2000).
58. Olsson R, Boberg KM, de Muckadell OS et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129(5), 1464-1472 (2005).
59. Lindor KD, Kowdley KV, Luketic VA et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50(3), 671-613 (2009). Recent randomized, double-blind controlled trial showing an increased adverse effect of high-dose ursodiol.
60. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J. Pediatr. Gastroenterol. Nutr. 47(1), 61-67 (2008). Interesting study of vancomycin as a possible novel pharmacologic agent for the tratment of PSC.
61. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin. Transpl. 1, 17-37 (1998).
62. Wiesner RH. Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract. Res. Clin. Gastroenterol. 15(4), 667-680 (2001).
63. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am. J. Gastroenterol. 102(1), 107-114 (2007).
64. Khettry U, Keaveny A, Goldar-Najafi A et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum. Pathol. 34(11), 1127-1136 (2003).
65. Kugelmas M, Spiegelman P, Osgood MJ et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 9(7), 727-732 (2003).
66. Brandsaeter B, Schrumpf E, Bentdal O et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl. 11(11), 1361-1369 (2005).
67. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 14(2), 245-251 (2008).
68. Alabraba E, Nightingale P, Gunson B et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 15(3), 330-340 (2009).
69. Graziadei IW, Wiesner RH, Batts KP et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29(4), 1050-1056 (1999).
70. Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 38(1), 210-217 (2003).
71. Lankisch TO, Mourier O, Sokal EM et al. AIRE gene analysis in children with autoimmune hepatitis type I or II. J. Pediatr. Gastroenterol. Nutr. 48(4), 498-500 (2009).
72. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 33(1), 99-103 (1998).
73. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J. Gastroenterol. 14(3), 331-337 (2008). Reviews autoimmune liver disease associated with inflammatory bowel disease.
74. Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J. Gastroenterol. 14(21), 3360-3367 (2008).
75. Mehendiratta V, Mitroo P, Bombonati A et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 7(1), 98-103 (2009).
76. Saadah OI, Smith AL, Hardikar W. Long-term outcome of autoimmune hepatitis in children. J. Gastroenterol. Hepatol. 16(11), 1297-1302 (2001).
77. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J. Clin. Gastroenterol. 39(9), 819-825 (2005).
78. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J. Hepatol. 33(3), 371-375 (2000).
79. Hennes EM, Oo YH, Schramm C et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am. J. Gastroenterol. 103(12), 3063-3070 (2008).
80. Chatur N, Ramji A, Bain VG et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 25(4), 723-727 (2005).
81. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am. J. Gastroenterol. 94(1), 241-248 (1999).
82. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig. Dis. Sci. 46(6), 1321-1327 (2001).
83. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J. Clin. Gastroenterol. 38(9), 805-809 (2004).
84. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol. 13(23), 3232-3236 (2007).
85. Luth S, Kanzler S, Frenzel C et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J. Clin. Gastroenterol. DOI: 10.1097/ MCG.0b013e318157c614 (2008) (Epub ahead of print).
86. Floreani A, Rizzotto ER, Ferrara F et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am. J. Gastroenterol. 100(7), 1516-1522 (2005).
87. Dubinsky MC, Vasiliauskas EA, Singh H et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125(2), 298-303 (2003).
88. de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4(12), 686-694 (2007).
89. Ierardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin. Drug Investig. 26(11), 673-676 (2006).
90. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin. Rheumatol. 26(4), 578-581 (2007).